ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HCM Hutchmed (china) Limited

290.00
-14.00 (-4.61%)
Last Updated: 16:21:02
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.00 -4.61% 290.00 289.00 293.00 312.00 287.00 312.00 85,714 16:21:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 304p. Over the last year, Hutchmed (china) shares have traded in a share price range of 173.60p to 338.00p.

Hutchmed (china) currently has 871,256,270 shares in issue.

Hutchmed (china) Share Discussion Threads

Showing 1926 to 1949 of 4100 messages
Chat Pages: Latest  80  79  78  77  76  75  74  73  72  71  70  69  Older
DateSubjectAuthorDiscuss
21/4/2019
14:57
I am looking forward to the AGM this coming week, my eight or ninth and always a good opportunity to catch up with a few long term strategic Investors
nerdofsteel
20/4/2019
05:59
“The current pace of development of the biotech ecosystem in China is remarkable,” said Simon To, Chi-Med’s chairman. “It is being fuelled by the major unmet medical needs in China, systemic regulatory reforms that are accelerating new drug innovation and deepening market access.”

“We expect the listing to enhance liquidity for our shareholders and strengthen our access to capital with a view to ensuring that we can fully realise the considerable potential of our drug portfolio and continue to strive to become a global biopharmaceutical company,” he added.

If it will also reduce the spread between bid/offer it will also help liquidity as mentioned above. Bring it on. I may buy even more if that improves drastically!

lauders
18/4/2019
14:13
slightly off topic but here is an article from Brad Loncar's China ETF website today (we are a constitute of his China Biotech ETF)

hxxps://www.loncarfunds.com/Junshi

The article is an interview with the CEO of Junshi but it is interesting in that he talks about the NDRL and also the general state of the Biopharma industry in China

nerdofsteel
15/4/2019
13:48
Asked the CFO about this last month. He said main reason for CKHH to reduce below 50% would be to change the way that HCM was consolidated in the HH accounts. Apparently new management there is under pressure to increase margins.. Not sure about the details but all round it does make sense.
dbadvn
15/4/2019
07:46
I did ask the BOD about an HK listing at last years AGM and their view was "never say never"........the market should like this news, the liquidity aspect should be a major positive
nerdofsteel
15/4/2019
07:36
Note there's a split in London but NOT in the USA.Canny move.The UK has this naive appreciation of low priced stocks but arguably the reverse is true in the US.A heavyweight price in the States is a sign of quality.
steeplejack
15/4/2019
07:33
"I am also intrigued by the reduction of holdings by CKHH to increase liquidity, something that has been mooted by them previously..."Yes,below 50%,good move,the market will like that.
steeplejack
15/4/2019
07:31
Never sure about share-splits. Makes the shares seem more attractive to many as they are a lower price and you can buy more for your money, but never seemed to do Berkshire Hathaway much harm to never split. Still, it will probably end well. Just have to await the reaction now.
lauders
15/4/2019
07:26
Fantastic news in my opinion, I have wondered for some time whether the Company may consider a HK listing rather than any future additional issues on NASDAQ. This is yet another example of the Co's globalisation! I am also intrigued by the reduction of holdings by CKHH to increase liquidity, something that has been mooted by them previously...

"CKHH has also informed Chi-Med that it intends to reduce its shareholding to below 50% both to improve liquidity in Chi-Med’s Shares and in order that Chi-Med would no longer be a consolidated subsidiary in the financial statements of CKHH."

nerdofsteel
15/4/2019
07:09
Hong Kong listing could stimulate interest.Road shows etc.10 for 1 split planned for AIM quote.

The Company has made the application to the SEHK at this time to facilitate a potential listing on the SEHK in the third quarter of 2019.

In connection with the Offering, the Company proposes to (a) implement a share split whereby one share will be sub-divided into 10 shares and (b) amend certain provisions of the Company's Articles of Association to reflect certain requirements of the SEHK. Concurrent with the proposed share split, the ADS ratio will be changed from 1 ADS representing one-half Share to 1 ADS representing 5 Shares, so that the foregoing share split will not affect the trading price of our ADSs. The share split will, however, result in a reduction in the price of each Share trading on the AIM market such that, immediately following the share split, the price of each Share on AIM will be one-tenth of the price prior to the split.

steeplejack
13/4/2019
11:39
Barclays PLC purchased a new position in HUTCHISON CHINA/S (NASDAQ:HCM) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 34,954 shares of the company’s stock, valued at approximately $807,000.

hxxps://www.fairfieldcurrent.com/news/2019/04/13/34954-shares-in-hutchison-china-s-hcm-purchased-by-barclays-plc.html

Can't say I blame them

I continue to buy

nerdofsteel
12/4/2019
08:11
Yes, and it would be fantastic if we manage to get Elunate on the NDRL in the next few months. Currently just over 1000 patients are on it, with a target patient population of 50,000 so expanded access even at a lower price benefits patients and Chi-Med.
nerdofsteel
12/4/2019
02:08
Good interview as usual from CH NofS. Your link didn't work for me though (just need to change the first "h" to "H" to make it work by the way), so I went to the company's homepage and just watched it by clicking the link there:

I like the fact he talked about the IP and how it is protected in China as well as how reducing the drug costs is not a bad thing but rather the opposite: helps more patients and in the end HCM.

lauders
11/4/2019
18:39
CEO interview on CNBC Hong Kong

hxxps://www.chi-med.com/wp-content/uploads/2019/04

nerdofsteel
09/4/2019
17:38
Thankyou GGL! ;o-)
nerdofsteel
09/4/2019
14:48
Nerdofsteel
9 Apr '19 - 14:39 - 1860 of 1860
0 0 0
New Trinity Delta note released today:-

grupo guitarlumber
09/4/2019
14:39
New Trinity Delta note released today:-

hxxps://www.trinitydelta.org/research-notes/aacr-2019-savolitinib-in-the-spotlight-in-nsclc/

nerdofsteel
05/4/2019
02:19
A very brief snippet from a recent interview (2nd April). Good that the weekend news generated interest within the scientific community.
lauders
03/4/2019
09:13
My tales of woe on the price is that I bought a very large holding between around £3.50 and £4.50 and sold them all back in 2013, I then bought a large holding again in mid 2016 for circa £18.00 per share and have been buying ever since but clearly wish I hadn't sold at all. I continue to buy and will be holding for at least 10 years. Brilliant Company with fantastic management! Looking forward to the AGM again in a couple of weeks time.
nerdofsteel
03/4/2019
08:34
I think a five-fold increase is certainly possible over a long period of time, maybe 10 years or so. Looking at forecast revs and earnings, on the assumption that there are no major pipeline crashes, and looking at valuation metrics of similar companies (Genmab, Incyte etc) - Incyte is a great example - it went up 5 fold in 2 years from Jan 2013 as its pipeline and launches started to kick in
nerdofsteel
02/4/2019
09:13
I am certainly relieved holder now. Have it in my ISA, SIPP and daughter's child trust so hoping for five-fold increase from here as my average price is GBP 40.
learningtrader
01/4/2019
16:57
Now back in >$30 territory, where it was prior to the pipeline news in late Dec, common sense starting to prevail
nerdofsteel
01/4/2019
10:13
Have to wait for the US market to open to see if we can go back towards 5000p faster NofS!
lauders
01/4/2019
10:03
Plenty of very positive Tweets and coverage from AACR2019 in Atlanta yesterday
nerdofsteel
Chat Pages: Latest  80  79  78  77  76  75  74  73  72  71  70  69  Older

Your Recent History

Delayed Upgrade Clock